Ultime notizie per Elanco Animal Health (NYSE:ELAN) Azioni

Elanco Animal Health

Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.

Long Ideas

News

Markets

Tech

Media

Trading Ideas

ASML

CHWY

CLOV

ELAN

RGTI

L&#39;esperto prevede un forte aumento di determinati titoli quantistici, supportato dai recenti sviluppi tecnologici.

Jim Cramer: ecco quali titoli quantistici domineranno il mercato

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health Inc

ELANIX BIOTECHNOLOGIES AG by ELANIX BIOTECHNOLOGIES AG

JP Morgan analyst Jeremy Tonet maintains CenterPoint Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNP#NYSE">CNP</a>) with a Neutral and raises the price target from $38 to $39.

Price Target

Analyst Ratings

JP Morgan Maintains Neutral on CenterPoint Energy, Raises Price Target to $39

Diageo plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>) shares are trading lower on Monday after the company reported <a target="_blank" href="https://www.diageo.com/en/news-and-media/press-releases/2025/diageo-issues-fiscal-25-q3-trading-statement" rel="noreferrer noopener">a third-quarter fiscal 2025</a> trading update that showed steady growth in organic net sales and progress on its operational transformation efforts.
The maker of Smirnoff and Guinness posted $4.4 billion in net sales for the quarter ended March 31, marking a 2.9% increase year-over-year. Organic net sales rose 5.9%, driven by stronger pricing and shipment volumes.
The company&#8217;s performance in the third quarter benefited from favorable phasing, which is estimated to have contributed approximately 4% to the group&#8217;s organic net sales growth. This positive impact was primarily observed in North America, with a lesser contribution from the Latin America and Caribbean region. It is anticipated that this favorable phasing will reverse in the fourth quarter.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/mid-cap/25/05/45491961/why-is-txnm-energy-stock-soaring-on-monday" rel="noreferrer noopener">Why Is TXNM Energy Stock Soaring On Monday?</a>
Diageo reported a 6% organic net sales growth in North America, primarily driven by strong shipment growth in U.S. Spirits. While U.S. Spirits experienced strong shipment growth, Diageo noted that the overall U.S. Spirits category was softer.
U.S. Spirits organic net sales were up 7%. The gain was supported by restocking and import pull-forwards in anticipation of new tariffs.
Latin America and the Caribbean delivered a 29% organic sales jump, rebounding from last year&#8217;s inventory correction and buoyed by improved consumer sentiment in Brazil and Mexico.
In contrast, Europe saw flat growth as solid momentum in Guinness was offset by continued softness in spirits. Asia Pacific posted modest gains, mainly due to easier year-ago comparisons, while Africa recorded 10% organic growth, fueled by strong demand in East Africa and Ghana.
Chief Executive Debra Crew said the company is &#8220;on track&#8221; to meet its fiscal 2025 outlook despite macroeconomic uncertainty and new tariffs on U.K. and EU imports into the U.S. Diageo expects the total impact of these tariffs to reach approximately $150 million annually, though it aims to mitigate roughly half of that through cost controls and pricing strategies.
As part of its newly launched &#8220;Accelerate&#8221; initiative, Diageo plans to generate approximately $3 billion in free cash flow annually starting in fiscal 2026. The program also includes a $500 million cost reduction plan over three years and targets a reduction in leverage to 2.5–3.0x net debt to EBITDA by fiscal 2028.
Diageo reaffirmed its fiscal 2025 guidance for the full year, expecting a sequential improvement in organic net sales growth during the second half. However, it anticipates a slight decline in organic operating profit year-over-year, in line with the first half, due in part to ongoing tariff pressures.
Capital expenditures for the year are expected to be near the upper end of the $1.3 to $1.5 billion range, and the company projects a slightly lower effective interest rate than the 4.3% recorded in fiscal 2024. The full-year results will also introduce a revised tax reporting method.
Related ETFs: Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>), iShares Global Consumer Staples ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KXI#NYSE">KXI</a>).
Price Action: DEO shares are trading lower by 1.02% to $113.88 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45173740" target="_blank" rel="noreferrer noopener">5 Great Income Buys For The Coming Downturn</a></li>
</ul>
Image by&nbsp; Evgeniyqw via Shutterstock

Earnings

Guidance

Movers

iShares S&P Globalnsumer Staples Sector Index Fund

Smirnoff, Guinness Parent Diageo Talks About Adverse Tariffs Impact

Morgan Stanley analyst Adam Jonas maintains Adient (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADNT#NYSE">ADNT</a>) with a Underweight and lowers the price target from $17 to $16.

ADNT

Morgan Stanley Maintains Underweight on Adient, Lowers Price Target to $16

Cantor Fitzgerald analyst C J Muse maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Neutral and raises the price target from $230 to $250.

Cantor Fitzgerald Maintains Neutral on Analog Devices, Raises Price Target to $250

Morgan Stanley analyst Tejas Savant maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Overweight and lowers the price target from $26 to $18.

Morgan Stanley Maintains Overweight on 10x Genomics, Lowers Price Target to $18

The fear of rejection and failure is often presented as the biggest fears on the path to success. However, real estate investor Grant Cardone believes that <a href="https://www.tiktok.com/@grantcardone/video/7503897248464489770?lang=en">rejection isn't as bad as people say it is</a>. Cardone has dealt with plenty of rejection. Potential customers have said no to his offer, people have said that they don't like him, and he's been rejected in other ways.
Rejection is a normal part of life, but it can be a sign that you're making a name for yourself. Although the word "no" may not be pleasant at the moment, it's worse to hear nothing at all. Cardone would happily take rejection over another scenario that he believes is worse.
"Rejection is way less painful than being ignored," Cardone said.&nbsp;&nbsp;
Cardone explains why rejection may be a good thing and that being ignored is worse than rejection.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
<h2 class="wp-block-heading">Everyone Gets Ignored In The Beginning</h2>
Cardone explains that successful actors and athletes were ignored in the beginning. They didn't receive any acknowledgement for their interest in their craft or how hard they were working.
However, this truth doesn't only apply to athletes and actors. It also applies to people who are getting started as content creators, individuals who are picking up a side hustle to make ends meet, and people who have just started with their wealth-building journeys.
While some people prefer to work and live without much fanfare, businesses never get the opportunity to grow if they are always ignored. If you get more people to know about you, rejection becomes normal. However, it's better to have some rejection and criticism than it is to have no one know about your business or services.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
<h2 class="wp-block-heading">Criticism Comes After You Get Noticed</h2>
People don't criticize nobodies. The critics only get louder as you make a bigger name for yourself. That's why Cardone doesn't mind rejection. Each criticism or rejection further validates that he is reaching more people.
When Cardone gets more visibility, it translates into more revenue. More people buy his books and programs, and he also attracts more investors for Cardone Capital. Visibility can also lead to more visibility, as more people want to have him on their podcasts and radio shows.&nbsp;
<h2 class="wp-block-heading">Converting Criticism Into Positive Momentum</h2>
Cardone is well-versed in turning criticism into positive momentum. He's been told that he wouldn't have a good career out of school and has been on the receiving end of numerous hate messages.&nbsp;
See Also: Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>.&nbsp;
Although many people like Cardone, there are also plenty of people who do not like him. However, that may actually be a good thing. Cardone said in his book, "The 10X Rule," that you can become the president if you get half of the population to hate you. Having that amount of criticism can result in the other half of the population liking your work and what you are doing.
However, Cardone also uses criticism as fuel. His approach is to prove the haters wrong and silence them with his success. In the video clip, he explains that he remembers people who fired him or said that he wouldn't be successful.&nbsp;
He can shut down the critics by outworking the competition, and in doing so, he attracts more critics. It's a positive feedback loop built on the negative sentiments of others that contributes to Cardone's success. He doesn't care what you think about him. Instead, he cares about what he thinks about himself.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.30/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

Grant Cardone Explains Why It's Good To Hear No: 'Rejection Is Way Less Painful Than Being Ignored'

WIIM

NFLX

Netflix shares are trading lower after JPMorgan downgraded the stock from Overweight to Neutral despite raising the price target from $1150 to $1220.

CRWV

CoreWeave shares are trading higher after the company announced a $1.5B private placement offering of senior notes due 2030.

RDDT

Reddit shares are trading lower after Wells Fargo downgraded the stock from Overweight to Equal-Weight and lowered its price target from $168 to $115.

Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) has outperformed the market over the past 5 years by 1.05% on an annualized basis producing an average annual return of 15.94%. Currently, Lattice Semiconductor has a market capitalization of $7.05 billion. 
Buying $100 In LSCC: If an investor had bought $100 of LSCC stock 5 years ago, it would be worth $214.35 today based on a price of $51.30 for LSCC at the time of writing.
<h3>Lattice Semiconductor's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747664112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LSCC

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

BMO Capital analyst Fadi Chamoun maintains FedEx (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FDX#NYSE">FDX</a>) with a Market Perform and lowers the price target from $275 to $260.

BMO Capital Maintains Market Perform on FedEx, Lowers Price Target to $260

ASST

Asset Entities Shares Resume Trading

Israel-based international cargo shipping company ZIM Integrated Shipping Services Ltd.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares are trading higher on Monday after the company reported a&nbsp;first-quarter sales increase of&nbsp;28% year over year (Y/Y) to&nbsp;$2.01 billion,&nbsp;beating&nbsp;<a href="https://www.benzinga.com/pressreleases/25/05/n45489831/zim-reports-financial-results-for-the-first-quarter-of-2025" target="_blank" rel="noreferrer noopener">the consensus of&nbsp;$1.85 billion</a>.
Revenue was driven by the increase in freight rates as well as carried volume. Carried volume in the quarter was 944 thousand TEUs, an increase from 846 thousand TEUs a year ago quarter. The cargo shipping company&#8217;s average freight rate per TEU stood at $1,776&nbsp;(+22% Y/Y) in the quarter.
Adjusted EBITDA escalated&nbsp;82%&nbsp;Y/Y&nbsp;to&nbsp;$779&nbsp;million, with margins of&nbsp;39% vs.&nbsp;27%&nbsp;in the prior year quarter. The company generated an EPS of&nbsp;$2.45, vs&nbsp;75 cents last year,&nbsp;<a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">beating the consensus of&nbsp;$1.87</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/25/05/45335936/no-cargo-vessels-en-route-from-china-to-california-for-first-time-since-pandemic" rel="noreferrer noopener">No Cargo Vessels En Route From China To California For First Time Since Pandemic</a>
Operating cash flow for the year was&nbsp;$855 million, compared to&nbsp;$326 million a year ago.&nbsp;Capital expenditures were&nbsp;$78 million during the quarter versus&nbsp;$24 million a year ago.
ZIM&#8217;s&nbsp;total cash position increased&nbsp;by&nbsp;$230&nbsp;million from&nbsp;$3.14&nbsp;billion as of&nbsp;December 31, 2024,&nbsp;to&nbsp;$3.37 billion&nbsp;as of&nbsp;March 31, 2025.
ZIM&#8217;s&nbsp;net leverage ratio was 0.6x as of March-end, compared to 0.8x as of&nbsp;December 31, 2024.
Eli Glickman, ZIM President &amp;&nbsp;CEO,&nbsp;said, &#8220;As we look toward the remainder of the year, the operating environment is highly uncertain, driven by a range of factors impacting global trade and economic expectations.&#8221;
&#8220;We continuously assess how to best allocate capacity and have taken steps to modify our network to match the changes in cargo flow from&nbsp;China&nbsp;and other Southeast Asian markets into&nbsp;the United States, including within the last week, which underscores the agile nature of our commercial strategy.&#8221;
Dividend: The Board of Directors declared a regular cash dividend of&nbsp;$89 million ($0.74&nbsp;per share), payable on June 9, 2025, to shareholders of record as of June 2.
Glickman added, &#8220;We are confident that we have built a resilient business and will continue to benefit from the strategic investment in our fleet with larger, more modern, cost-effective capacity, approximately 40% of which is LNG-fueled. Supported by our lower cost base, we believe ZIM is well positioned to drive profitable growth over the long term.&#8221;
2025 Outlook: ZIM reaffirmed an adjusted EBITDA outlook of $1.6 billion to $2.2 billion and an adjusted <a href="https://www.benzinga.com//node/44276789" target="_blank" rel="noreferrer noopener">EBIT of $350 million to $950 million</a>.
&#8220;We enter 2025 with a more resilient business and modern cost- and fuel-efficient capacity,&nbsp;40%&nbsp;of which is LNG-fueled. While acknowledging that our industry is highly volatile, exacerbated by current uncertainty related to geopolitics, international political dynamics, and economic, fiscal and monetary policies, we are confident in our agile approach and competitive position in the industry,&#8221;&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">added Glickman</a>.
Investors can gain exposure to the stock via&nbsp;ETF Series Solutions U.S. Global Sea to Sky Cargo ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEA#NYSE">SEA</a>) and&nbsp;SonicShares Global Shipping ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOAT#NYSE">BOAT</a>).
Price Action: ZIM shares are trading higher by 11.8% to $20.49 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://in.benzinga.com/personal-finance/25/05/45183970/behind-the-empty-docks-how-trumps-145-tariffs-are-gutting-u-s-supply-chains" target="_blank" rel="noreferrer noopener">Behind The Empty Docks: How Trump&#8217;s 145% Tariffs Are Gutting U.S. Supply Chains</a></li>
</ul>
Image via Shutterstock

Equities

Large Cap

BOAT

This International Cargo Shipping Company Sees Macro Uncertainty But Is Making More Money Per Cargo

BMO Capital analyst Simeon Siegel maintains National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) with a Market Perform and raises the price target from $13 to $19.

BMO Capital Maintains Market Perform on National Vision Holdings, Raises Price Target to $19

JP Morgan analyst Tien-Tsin Huang upgrades Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) from Neutral to Overweight and raises the price target from $88 to $98.

Upgrades

CTSH

JP Morgan Upgrades Cognizant Tech Solns to Overweight, Raises Price Target to $98

The maker of commercial vehicle autonomous driving technology has updated its application to list in Hong Kong, boasting a market value of $1.2 billion
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19103542/Cidi-0519-900x600-1.png" alt="" class="wp-image-13085" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19103542/Cidi-0519-900x600-1.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19103542/Cidi-0519-900x600-1-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/19103542/Cidi-0519-900x600-1-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul class="wp-block-list">
<li>CiDi Inc. has applied for a Hong Kong IPO, boasting its status as China's largest maker of autonomous driving technology for commercial vehicles</li>
<li>The company has been drowning in red ink over the last three years, with combined losses of nearly 1.1 billion yuan</li>
</ul>
DJI Technology&nbsp;is a household name in corporate China, soaring to fame as one of the country's – and world's – top drone makers. Valued at 120 billion yuan ($16.6 billion), the company is often considered the brainchild of founder Wang Tao, one of China's best-known entrepreneurs.
Yet a more remarkable figure may be the man behind Wang. Here, we're referring to Li Zexiang, Wang's mentor at the Hong Kong University of Science and Technology, who not only inspired Wang intellectually but also provided him with hands-on support. Li also served a stint as DJI's chairman, helping the company to cultivate new talent, providing management advice, and using his connections to help his protégé. It's often said that "Without Li Zexiang, there would be no DJI."
Now, Li, who could perhaps be considered the "godfather of DJI," is looking for his own place in the spotlight, filing a new application this month to list his autonomous driving unicorn,&nbsp;CiDi Inc.,&nbsp;on the Hong Kong Stock Exchange. That application followed an&nbsp;<a href="https://thebambooworks.com/cidi-sets-ipo-course-with-its-self-driving-trucks/">earlier one</a>&nbsp;last November, which lapsed after the company failed to complete its listing within six months.
CiDi specializes in autonomous driving products and solutions for commercial vehicles, focusing on mining and big-rig trucks, as well as vehicle-to-everything (V2X) technology and intelligent perception solutions.
Its latest&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107349/documents/sehk25050802066.pdf">listing application</a>&nbsp;shows its revenue has ramped up steadily over the last three years, growing more than tenfold from 31 million yuan in 2022 to 410 million yuan last year. Despite that rapid growth, the company is still bleeding red ink, like many of its peers in the autonomous driving industry. Its losses have totaled just over 1 billion yuan over the last three years, including a 581 million yuan loss in 2024.
Investors have high hopes for companies like CiDi, in no small part due to strong government policy support. Last year, Beijing issued a document directly tied to CiDi's sweet spot, titled "Guidelines on Advancing Intelligent Mining Construction to Promote Mine Safety Development." It emphasized the importance of mining safety, in a country known for its mining accidents, and thus the necessity of speeding up development of unmanned mining trucks.&nbsp;
Such prioritization often results in the channeling of big government funds to targeted sectors, not to mention greasing the wheels of getting necessary permits for everything from vehicle testing to setting up new production facilities. That should give the entire intelligent mining truck sector a significant leg up in the form of not only government support, but also demand from mining companies that are mostly state-owned.
According to third-party market data in CiDi's listing document, China's autonomous driving mining truck solutions industry was already worth 1.9 billion yuan in 2024, and is expected to explode to 39.6 billion yuan by 2030, representing annual growth of 65.3% over that time.
<h4 class="wp-block-heading">Incubation maestro</h4>
In a sector with such big potential, technological prowess is a key factor in determining who will dominate. CiDi could be a player to watch in that regard, as founder Li Zexiang brings a wealth of ability, knowledge and experience in scientific research. Before CiDi, other companies that Li helped to nurture include not only DJI, but also QKM, Hai Robotics, ePropulsion, and Narwal. Similarly, he's likely to spare no effort on CiDi, which, unlike the others that were started by others, is his only "true biological child."
Notably, CiDi was the first company in China to deliver fully unmanned pure-electric mining trucks, and among the earliest autonomous driving companies to launch commercial V2X products. Its Train Autonomous Perception System (TAPS) is currently the only product with independently developed safety perception in the domestic market.
CiDi already heads certain segments of its class, ranking first in China's autonomous driving mining truck solutions market by revenue in 2024.
The question for the company and most of its peers has always been about their big appetite for cash. While its growth has been impressive, its 410 million yuan in revenue last year was far less than its costs, including 310 million yuan in cost of sales; 300 million yuan in administrative expenses; 60 million yuan for sales and marketing; and 193 million yuan for R&amp;D.
The company's gross margins for the past two years have also been relatively low for a technology-driven company, at 20.2% and 24.7%. Becoming profitable will hinge on a combination of cost optimization and achieving economies of scale, which looks unlikely to happen in the short term.
<h4 class="wp-block-heading">Invest in the jockey</h4>
While the road to profits may be long, CiDi has found plenty of fans to help it along the way. Backed by Li Zexiang's personal charisma, the company has raised 1.49 billion yuan over eight rounds of pre-IPO funding from backers that include industry giants such as HongShan, formerly known as Sequoia China, Xin Ding Capital, Baidu Ventures and Legend Holdings. And its latest valuation of 9 billion yuan gives it a hefty price-to-sales (P/S) ratio of 22 times.
In 2023, another company associated with Li Zexiang,&nbsp;Googol Technology&nbsp;(301510.SZ), came charging out of the gate in its Shenzhen IPO, with its stock rising nearly sixfold from a listing price of 12 yuan to close at 59.38 yuan on its first trading day. Googol currently enjoys a meteoric forward price-to-earnings (P/E) of 250 times, with a market valuation of 13.2 billion yuan. Such a rapid rise has led some to hope that CiDi could get a similarly high valuation and become a hot IPO if it makes it to market this time.
Li Zexiang's star power could certainly help in that regard, proving a golden investing adage that people should "Invest in the jockey, not the horse."

Asia

Travel

IPOs

Opinion

CiDi Drives Toward IPO, Powered By 'Godfather Of Drones'

BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Outperform and raises the price target from $24 to $28.

ACAD

BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Raises Price Target to $28

Asset Entities Shares Halted On Circuit Breaker To The Downside, Stock Now Up 6.91%

Stifel analyst W. Andrew Carter maintains Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) with a Hold and lowers the price target from $270 to $250.

Stifel Maintains Hold on Lowe's Companies, Lowers Price Target to $250

Stifel analyst Jonathan Block maintains IDEXX Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) with a Hold and raises the price target from $460 to $510.

IDXX

Stifel Maintains Hold on IDEXX Laboratories, Raises Price Target to $510

Press Releases

Elanco to Participate in Upcoming Investor Conferences

Elanco Enters Agreement with Medgene to Commercialize Highly Pathogenic Avian Influenza Vaccine in Dairy Cattle

Elanco Animal Health Reports Fourth Quarter and Full Year 2024 Results

Elanco Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

Elanco Confirms Date and Conference Call for First Quarter 2025 Financial Results Announcement

Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day

Legal

ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown

Elanco Animal Health Reports First Quarter 2025 Results

Elanco to Participate in the Upcoming Investor Conferences

TARS

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Elanco Animal Health

Notizie

Ultime notizie per Elanco Animal Health (NYSE:ELAN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO